HTG Molecular Diagnostics Inc. (NASDAQ: HTGM) is -6.68% lower on its value in year-to-date trading and has touched a low of $0.27 and a high of $1.64 in the current 52-week trading range. The HTGM stock was last observed hovering at around $0.65 in the recent trading session, with the current loss setting it 0.0% off its average median price target of $1.25 for the next 12 months. It is also 67.5% off the consensus price target high of $2.00 offered by 4 analysts, but current levels are 7.14% higher than the price target low of $0.70 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $0.65, the stock is -6.12% and 13.24% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.81 million and changing -1.02% at the moment leaves the stock 8.05% off its SMA200. HTGM registered -58.54% loss for a year compared to 6-month loss of -9.03%. The firm has a 50-day simple moving average (SMA 50) of $0.6548 and a 200-day simple moving average (SMA200) of $0.5309.
The stock witnessed a -1.50% gain in the last 1 month and extending the period to 3 months gives it a 113.56%, and is -2.89% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.54% over the week and 13.33% over the month.
HTG Molecular Diagnostics Inc. (HTGM) has around 108 employees, a market worth around $42.59M and $18.20M in sales. Distance from 52-week low is 142.73% and -60.47% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.00%).
HTG Molecular Diagnostics Inc. (HTGM) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for HTG Molecular Diagnostics Inc. (HTGM) is a “Overweight”. 4 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
HTG Molecular Diagnostics Inc. is expected to release its quarterly report on 08/11/2020 and quarterly earnings per share for the current quarter are estimated at -$0.08 with sales reaching $1.79M over the same period.The EPS is expected to grow by 15.30% this year, but quarterly earnings will post -41.20% year-over-year. Quarterly sales are estimated to shrink -67.80% in year-over-year returns.
HTG Molecular Diagnostics Inc. (HTGM) Top Institutional Holders
42 institutions hold shares in HTG Molecular Diagnostics Inc. (HTGM), with 5.3M shares held by insiders accounting for 7.87% while institutional investors hold 63.07% of the company’s shares. The shares outstanding are 64.57M, and float is at 57.61M with Short Float at 1.28%. Institutions hold 58.10% of the Float.
The top institutional shareholder in the company is Nantahala Capital Management, LLC with over 5.06 million shares valued at $1.64 million. The investor’s holdings represent 7.54% of the HTGM Shares outstanding. As of Mar 30, 2020, the second largest holder is Cowen Prime Services LLC with 4.46 million shares valued at $1.45 million to account for 6.64% of the shares outstanding. The other top investors are Perkins Capital Management, Inc. which holds 2.43 million shares representing 3.63% and valued at over $0.79 million, while Vanguard Group, Inc. (The) holds 2.44% of the shares totaling 1.64 million with a market value of $0.53 million.
HTG Molecular Diagnostics Inc. (HTGM) Insider Activity
A total of 13 insider transactions have happened at HTG Molecular Diagnostics Inc. (HTGM) in the last six months, with sales accounting for 8 and purchases happening 5 times. The most recent transaction is an insider sale by JOHNSON TIM B, the company’s Executive Chairman. SEC filings show that JOHNSON TIM B sold 5,718 shares of the company’s common stock on Dec 26 at a price of $0.72 per share for a total of $4110.0. Following the sale, the insider now owns 0.26 million shares.
HTG Molecular Diagnostics Inc. (HTGM): Who are the competitors?
The company’s main competitors (and peers) include Radius Health Inc. (RDUS) that is trading -44.20% down over the past 12 months. Affimed N.V. (AFMD) is 61.97% up on the 1-year trading charts. Short interest in the company’s stock has fallen -20.0% from the last report on May 14, 2020 to stand at a total of 0.89 million short shares sold with a short interest ratio of 0.12.